ライフサイエンスコーパス: adenosine receptor

1 enylxanthine (DPSPX) (0.1 muM; antagonist of adenosine receptors).

2 leep behavior independently of the one known adenosine receptor.

3 inopyridine or a selective agonist of the A3 adenosine receptor.

4 ine/paracrine signaling molecule through A2b adenosine receptor.

5 n mice lacking the renal proximal tubular A1 adenosine receptor.

6 rotection by ENT inhibitors involves the A2B adenosine receptor.

7 s as potent allosteric enhancers of the A(1) adenosine receptor.

8 ulfur phasing of the human G protein-coupled adenosine receptor.

9 asts, an effect regulated by A(2A) and A(2B) adenosine receptors.

10 investigated using agonist and antagonist of adenosine receptors.

11 mediated by astrocyte endocytic function and adenosine receptors.

12 tamate release via activation of presynaptic adenosine receptors.

13 ully an uncovered selectivity issue with the adenosine receptors.

14 cule found in adipose tissue depots, acts on adenosine receptors.

15 phosphate production by cells overexpressing adenosine receptors.

16 n (IFN)-gamma, lipopolysaccharide (LPS), and adenosine receptors.

17 y hydrolyzed extracellular AMP and activated adenosine receptors.

18 f presynaptic adenosine signaling through A1 adenosine receptors.

19 back, namely by providing the ligand for A2A adenosine receptors.

20 tumor immune responses via activation of A2A adenosine receptors.

21 stimulating effects through the blockade of adenosine receptors.

22 d CD73, and occurred via activation of A(2B) adenosine receptors.

23 expression and could balance signals through adenosine receptors.

24 Targets include the beta-adrenergic and adenosine receptors.

25 important GPCRs targets, including TAAR1 and adenosine receptors.

26 e.g., extracellular loop (EL) 3 in the A(2A) adenosine receptor].

27 tive migration through the engagement of the adenosine receptor 1 (ADORA1) and AKT signaling.

28 Chronic activation of adenosine receptor 2a (Adora2a) erodes tight junctions b

29 were treated with trolox, nifedipine, or the adenosine receptor 2A antagonist KW6002.

30 overexpress mRNA for dopamine receptor 2 and adenosine receptor 2a in the striatum, markers of medium

31 lanoma tumors, with the participation of the adenosine receptor 2A.

32 levels, as well as upregulated expression of adenosine receptor 3 (ADORA3) and genes related to adeno

33 The adenosine imbalance, which triggers adenosine receptor-3 signaling that decreases cAMP level

34 ed suppression of neuronal responses via the adenosine receptor A(1)R are essential for the regulatio

35 In addition, mice deficient in the adenosine receptor A(2A) were more susceptible to immuno

36 th agonists and antagonists directed against adenosine receptors A(2A)R and A(2B)R, we further demons

37 ides were synthesized to identify novel A(1) adenosine receptor (A(1)AR) agonists for CNS or peripher

38 selective and affine PET ligand for the A(1) adenosine receptor (A(1)AR).

39 These compounds were evaluated as A(2A) adenosine receptor (A(2A)R) agonists in a cAMP accumulat

40 ion of the full-length, wild-type human GPCR adenosine receptor (A(2A)R), and the bacterial transport

41 The cAMP-elevating A(2b) adenosine receptor (A(2b)AR) controls inflammation via i

42 The A(2B) adenosine receptor (A(2B)AR) was proposed as a novel tar

43 We demonstrate A(3) adenosine receptor (A(3)AR) agonism as a new target-base

44 gh the activation of the A(1)-subtype of the adenosine receptors (A(1)AR) is arrhythmogenic in the de

45 A(2B) adenosine receptors (A(2B)ARs) are the predominant adeno

46 An antagonist of the A2A adenosine receptor, a G-protein-coupled receptor that is

47 ge, new cholesterol-binding sites on the A2A adenosine receptor, a G-protein-coupled receptor that is

48 MD/FEP) in fragment optimization for the A2A adenosine receptor, a pharmaceutically relevant G protei

49 levels of ATP metabolites and expression of adenosine receptor A1, further evidence of cell damage a

50 unctions as a cytosine derivate to stimulate adenosine receptors A1 and A2a, which further activate d

51 tent binding across therapeutically relevant adenosine receptors (A1, A2a, and A3) as well as a poten

52 ave shown that bronchoalveolar epithelial A1-adenosine receptors (A1-AdoR) are activated in influenza

53 Adenosine and functional A1 adenosine receptor (A1AR) availability are supposed to m

54 The A1 adenosine receptor (A1AR) is an important G protein-coup

55 R) and AMPARs in the NAc, and explore how A1 adenosine receptor (A1AR) stimulation may reduce dopamin

56 In vivo imaging of the A1 adenosine receptor (A1AR) using (18)F-8-cyclopentyl-3-(3

57 Since central activation of A1 adenosine receptors (A1ARs) plays an important role in t

58 ve that stimulation of apically localized A1 adenosine receptors (A1ARs) triggers a Gi-Gbetagamma-pho

59 Here the authors show that adenosine receptor A2A drives pathological angiogenesis

60 (AD) had increased levels of the Gs-coupled adenosine receptor A2A in astrocytes.

61 hrough inhibition of p38 phosphorylation via adenosine receptors A2a-, A2b-, and protein kinase A-dep

62 appa-opioid receptor (KOR) and the human A2A adenosine receptor (A2A AR).

63 construct the activation pathways of the apo adenosine receptor (A2A), starting from an inactive conf

64 of compound 25 as a potent and selective A2A adenosine receptor (A2AAdoR) antagonist with reasonable

65 MR) spectroscopy with the wild-type-like A2A adenosine receptor (A2AAR) in solution provides a compre

66 non-nucleoside partial agonists for the A2A adenosine receptor (A2AAR).

67 Blockade of A2A adenosine receptors (A2AARs) and inhibition of monoamine

68 e remodeling and promotes dermal fibrosis by adenosine receptor (A2AR) activation.

69 Here, we show that engagement of A2A adenosine receptor (A2AR) acts as a checkpoint that limi

70 The A2A adenosine receptor (A2AR) is a G protein-coupled recepto

71 The cAMP-elevating, Gs protein-coupled A2a adenosine receptor (A2aR) is an evolutionarily conserved

72 lar dynamics simulations of thermostabilized adenosine receptor (A2AR) mutants embedded in either a l

73 Mice lacking A2A adenosine receptor (A2AR) or ecto-5'nucleotidase (an enz

74 se that generates adenosine CD73 and the A2A adenosine receptor (A2AR) that mediates adenosine signal

75 A2A adenosine receptors (A2ARs) are endogenous inhibitor of

76 drug screen revealed that antagonists of the adenosine receptor A2B (ADORA2B) are preferentially toxi

77 The adenosine receptor A2b is expressed in the vascular endo

78 Specific blockade of the A2B adenosine receptor (A2BAR) inhibited worm elimination an

79 The A2B adenosine receptor (A2BAR) is a Galpha(s)/alpha(q)-prote

80 report that, among these receptors, the A2b adenosine receptor (A2bAR) is highly expressed in adipoc

81 ypoxia-inducible factor 1a (Hif-1a), and A2B adenosine receptor (a2br) were increased by 10-, 4-, and

82 -methanocarba-5'-N-alkyluronamidoriboside A3 adenosine receptor (A3AR) agonists lacking an exocyclic

83 experimental neuropathic pain through the A3 adenosine receptor (A3AR, now known as ADORA3) signallin

84 Likewise, addition of antagonists for A2A adenosine receptors abolished the formation of DC-Treg c

85 The inhibition of CD73 or the inhibition of adenosine receptors abrogated the ATP effect on CXCL8 se

86 A1 adenosine receptor activation ameliorates ischemic AKI t

87 ry synapses from basolateral amygdala via A1 adenosine receptor activation and enhanced inhibitory sy

88 Using a novel cell-based assay to visualize adenosine receptor activation in real time, we found tha

89 A2b adenosine receptor activation induced CXCL8 via cAMP-pro

90 We propose that adenosine receptor activation suppresses inflammation an

91 fibrotic signal to cardiac fibroblasts by A2 adenosine receptor activation.

92 f ethanol that are due, at least in part, to adenosine receptor activation.

93 wild-type levels, suggesting a dependence on adenosine receptor activity.

94 vity in the Drosophila midgut, we identified adenosine receptor (AdoR) as a top candidate gene requir

95 te (ATP) as well as A(1), A2A, A2B, and A(3) adenosine receptor (ADOR) expression.

96 riptionally controlled pathways to pulmonary adenosine receptor (ADOR) signaling during ALI.

97 e hypothesized that signaling events through adenosine receptors (ADORA1, ADORA2A, ADORA2B, or ADORA3

98 o modulate their acidifying activity via the adenosine receptor ADORA2B and the pH-sensitive ATP rece

99 s for adenosine receptors implicated the A2B adenosine receptor (Adora2b) in mediating ENT-dependent

100 gical approaches, we determined that the A2B adenosine receptor (ADORA2B) is essential for adenosine-

101 s renal adenosine preferentially induced A2B adenosine receptor (ADORA2B) production and that enhance

102 sine or a specific antagonist to block A(2B) adenosine receptor (ADORA2B) signaling, we successfully

103 we show that many Receptor cells express the adenosine receptor, Adora2b, while Presynaptic (type III

104 atory treatment, but was evoked by exogenous adenosine receptor agonism, suggesting upstream impairme

105 Administration of the broad-spectrum adenosine receptor agonist 5'-N-ethylcarboxamidoadenosin

106 ily A(2B) receptors because the nonselective adenosine receptor agonist 5'-N-ethylcarboxamidoadenosin

107 es supplemented with adenosine, but not with adenosine receptor agonist 5'-N-ethylcarboxamidoadenosin

108 The effect of inosine was mimicked by the adenosine receptor agonist NECA and the A2B receptor ago

109 The adenosine receptor agonist NECA inhibited interferon-gam

110 rated that administration of a selective A2A adenosine receptor agonist to CD73-deficient mice result

111 Correspondingly, adenosine receptor agonist treatment also limited HDM-dr

112 Additionally, an adenosine receptor agonist was tested to study the mecha

113 epithelial (HK-2) cells with a selective A1 adenosine receptor agonist, chloro-N(6)-cyclopentyladeno

114 Certain A(3) adenosine receptor agonists are being developed for the

115 g protection, and they implicate inhaled A2B adenosine receptor agonists in ALI treatment.

116 we tested the P-gp interaction of some A(3) adenosine receptor agonists that are being developed for

117 lymeric (PEG-b-PLA) nanoparticles for use as adenosine receptor agonists.

118 ochrome P450 1A2), adenosine metabolism (for adenosine receptor and AMP deaminase), or catecholamine

119 le of enantiospecific recognition at the A2B adenosine receptor and opens new possibilities in ligand

120 f acute hypoxia with progressive blockade of adenosine receptors and nitric oxide synthase, and by mo

121 udies due to its reported lack of effects on adenosine receptors and phosphodiesterases.

122 characterize the physiological link between adenosine receptors and the gap junction coupling in end

123 els as a possible physiological link between adenosine receptors and the regulation of gap junction c

124 ightly regulated by Entpd1/Nt5e activity and adenosine receptors; and ADP-adenosine signaling play an

125 HIFI is inhibited by adenosine receptor antagonism and blockade of cyclooxyge

126 reduced electrophysiological response to an adenosine receptor antagonist and increased adenosine re

127 tive interaction between chronic exposure to adenosine receptor antagonist caffeine and genetic influ

128 Intranasal administration of the adenosine receptor antagonist caffeine substantially enh

129 This effect was prevented by a pan-adenosine receptor antagonist CGS15943, but not by A1 or

130 ith the synthesis of an A2-subtype selective adenosine receptor antagonist in only two steps.

131 We also show that treatment with an A1-adenosine receptor antagonist reduces the severity of lu

132 Controlled Randomized Study of the Selective Adenosine Receptor Antagonist Rolofylline for Patients H

133 trolled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients H

134 trolled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients H

135 transport small therapeutic amounts of an A1 adenosine receptor antagonist to the respiratory centers

136 Because caffeine (a nonselective adenosine receptor antagonist) and selective adenosine A

137 The consumption of caffeine (an adenosine receptor antagonist) correlates inversely with

138 ngested psychoactive drug and a nonselective adenosine receptor antagonist, alters CB function and ve

139 ttent intratumor injection of a nonselective adenosine receptor antagonist, aminophylline (AMO; theop

140 Caffeine (5, 10, or 15 mg/kg), a nonspecific adenosine receptor antagonist, dose-dependently and at h

141 in models, oral intake of caffeine, a potent adenosine receptor antagonist, interferes with acupunctu

142 latory effect on migration was blocked by an adenosine receptor antagonist, MRS1754, ARL67156, an ect

143 lfactory learning and memory by acting as an adenosine receptor antagonist.

144 Treatment with selective adenosine receptor antagonists indicated a contribution

145 Three novel families of A2B adenosine receptor antagonists were identified in the co

146 while P2Y-selective receptor antagonists or adenosine receptor antagonists were ineffective.

147 e reversed completely by two different A(2A) adenosine receptor antagonists without affecting T cells

148 n attractive scaffold for the preparation of adenosine receptor antagonists, is the low water solubil

149 two subsets of fluorinated nonxanthine A(2B) adenosine receptor antagonists.

150 lo[3.1.0]hexyl) adenosines favored high A(3) adenosine receptor (AR) affinity/selectivity, e.g., C2-p

151 2-arylethynyl groups were synthesized as A3 adenosine receptor (AR) agonists and screened in vivo (p

152 Studies have shown that adenosine receptor (AR) agonists can be either anti-infl

153 d (N)-methanocarba adenosine derivatives (A3 adenosine receptor (AR) agonists) to enhance radioligand

154 of caspase 1 was prevented by broad-spectrum adenosine receptor (AR) antagonism with caffeine and by

155 heir pharmacological characterization as A2A adenosine receptor (AR) antagonists by using in vitro an

156 wever, it is not clear whether adenosine and adenosine receptor (AR) antagonists play any roles in th

157 n-7-amines were designed as new human (h) A3 adenosine receptor (AR) antagonists.

158 cetamidopyridines as potent and selective A3 adenosine receptor (AR) antagonists.

159 We found a 20-fold increase in A(2B) adenosine receptor (AR) expression on GB compared with s

160 ate the potential of this scaffold to obtain adenosine receptor (AR) ligands.

161 ed the performance of an agonist-bound A(2A) adenosine receptor (AR) structure in retrieval of known

162 enosine and 2-chloroadenosine derivatives at adenosine receptor (AR) subtypes were studied with bindi

163 receptor (A(3)R) belongs to a family of four adenosine receptor (AR) subtypes which all play distinct

164 Although there are four adenosine receptor (AR) subtypes, the A2AAR is both high

165 deling of agonist binding to the human A(2A) adenosine receptor (AR) was assessed and extended in lig

166 1,5-c]pyrimidines as antagonists of the A(3) adenosine receptor (AR) was explored with the principal

167 Here, we show that activation of the A2A adenosine receptor (AR) with an FDA-approved A2A AR agon

168 ng mode of an antagonist series to the A(2A) adenosine receptor (AR).

169 with the main purpose of targeting the hA2A adenosine receptor (AR).

170 Stimulation of A2A adenosine receptors (AR) promotes anti-inflammatory resp

171 to G protein-coupled receptors including the adenosine receptors (AR), which are involved in a pletho

172 Because all adenosine receptors are expressed on osteoclasts, we det

173 Adenosine receptor (ARs) and P2Y receptors (P2YRs) that

174 m female patients, by engaging A(1) and A(3) adenosine receptors (ARs) and through reactive oxygen sp

175 stituted-1,2,4-triazolo[1,5-c]pyrimidines as adenosine receptors (ARs) antagonists has been explored.

176 Because A2B adenosine receptors (ARs) are important regulators of ma

177 Adenosine derivatives developed to activate adenosine receptors (ARs) revealed micromolar activity a

178 nts against homology models of the A3 and A1 adenosine receptors (ARs) with the goal to discover A3AR

179 We generated mice lacking all four adenosine receptors (ARs), Adora1-/-;Adora2a-/-;Adora2b-

180 affinity at both mouse (m) and human (h) A3 adenosine receptors (ARs), while a N(6)-p-sulfophenyleth

181 ntified as structurally novel antagonists at adenosine receptors (ARs).

182 -coupled receptors, the A1, A2A, A2B, and A3 adenosine receptors (ARs).

183 used a folding-defective mutant of human A1-adenosine receptor as a sensor to explore whether endoge

184 These studies identify ENT1 and adenosine receptors as key to the process of reestablish

185 Adenosine then acts on A1 adenosine receptors at neighboring excitatory Schaffer c

186 w series of allosteric modulators for the A1 adenosine receptor based on the 2-amino-3-(p-chlorobenzo

187 wever, systemic adverse effects may limit A1 adenosine receptor-based therapy for ischemic AKI, indic

188 romodulator in the mammalian retina, with A1 adenosine receptors being especially prevalent in the in

189 t observed in those animals administered the adenosine receptor blocker 8-(p-sulfophenyl)theophylline

190 on that is usually treated with caffeine, an adenosine receptor blocker that has powerful influences

191 pressive A2ARs that are potential targets of adenosine receptor blockers to enhance immune killing of

192 crosecond-timescale simulations of the A(2A) adenosine receptor bound to either of two agonists, aden

193 Most studies focus on effects of caffeine on adenosine receptors, but there is evidence for other, mo

194 We reengineered the human A(2A) adenosine receptor by replacing its third intracellular

195 mouse lung and that activation of A1-subtype adenosine receptors by adenosine contributes significant

196 The levels of mRNA expression of adenosine receptors, CD39 and CD73 of periodontitis samp

197 A2A adenosine receptors control pancreatic dysfunction in hi

198 e and ECM profiles; high expression of A(2B) adenosine receptors correlated with decreased expression

199 tic potentiation in oriens, whereas NMDA and adenosine receptors counteracted unpaired stratum oriens

200 Next, using 4 adenosine receptor-deficient mice and pharmacological ap

201 ceptor-deficient or renal proximal tubule A1 adenosine receptor-deficient mice.

202 at integrates gap junction coupling into the adenosine receptor-dependent signalling of endothelial c

203 nflammatory actions that were coupled to A2a adenosine receptor-dependent upregulation of tribbles ho

204 lates neovascularization in part through A2B adenosine receptor-dependent upregulation of vascular en

205 is lung carcinoma (LLC) cells, we found that adenosine receptor-dependent upregulation of VEGF produc

206 However, the therapeutic potential of adenosine receptor-directed ligands for neuroprotection

207 Knockdown of A2b adenosine receptor disrupted scl(+) hemogenic vascular e

208 or), opioid receptors, adrenergic receptors, adenosine receptors, dopamine receptor, and sphingosine

209 ion; Theophylline, an antagonist that blocks adenosine receptors (e.g. A2aR) in the brain responsible

210 '-methyluronamides containing known A(3) AR (adenosine receptor)-enhancing modifications, i.e., 2-(ar

211 antitumor immunity through the activation of adenosine receptors expressed on multiple immune subsets

212 Targeting retinal A1 adenosine receptors for ipRGC inhibition represents a po

213 The four subtypes of adenosine receptors form relevant drug targets in the tr

214 lective regulatory mechanism for fine-tuning adenosine receptor function in the nervous system.

215 adenosine receptor antagonist and increased adenosine receptor gene expression.

216 igned to obtain dual antioxidant-human A(2A) adenosine receptor (hA(2A) AR) antagonists.

217 Furthermore, mice lacking adenosine receptors had no defect in cyst formation.

218 Engineering the human A2A adenosine receptor has allowed structures to be solved i

219 Adenosine 5'-triphosphate and adenosine receptors have been identified in adult and fe

220 Agonists that target the A1, A2A, A2B and A3 adenosine receptors have potential to be potent treatmen

221 Furthermore, studies in genetic models for adenosine receptors implicated the A2B adenosine recepto

222 enosine and signaling events through the A2B adenosine receptor in lung protection.

223 Finally, genetic studies implicated the A2B adenosine receptor in netrin-1-mediated protection durin

224 gonist activation slows diffusion of the A2A adenosine receptor in the lipid bilayer.

225 nd its loss were investigated: expression of adenosine receptors in CB (A(2B)) was down-regulated and

226 Moreover, we evaluated the potential role of adenosine receptors in DF-EC interaction and if DF effec

227 not show any evidence of the involvement of adenosine receptors in DF-EC interaction.

228 In conclusion, the stimulation of adenosine receptors in hCMEC/D3 cells induces a Ca(2+) i

229 ine receptors (A(2B)ARs) are the predominant adenosine receptors in the intestinal epithelium.

230 esults suggest novel approaches to targeting adenosine receptors in the promotion of bone regeneratio

231 monstrate that adenosine, bound to A1 and A3 adenosine receptors, increases cytokine secretion by LPS

232 cAMP and VASP-P in the absence of ADP in an adenosine receptor-independent manner.

233 d that tissue-specific expression of the A2B adenosine receptor is responsible for the previously des

234 Comprehensive examination of adenosine receptor-knockout mice exposed to AKI demonstr

235 uation of emerging Rho-kinase inhibitors and adenosine receptor ligands that offer the potential to i

236 Activity of the conjugates as adenosine receptor ligands was tested by their capacity

237 compounds purchased, six novel high affinity adenosine receptor ligands were confirmed experimentally

238 n agents together with inhibitors of the A2A adenosine receptor may be required to enable the most ef

239 generation of adenosine or activation of A1-adenosine receptors may be beneficial in treating influe

240 These results indicate that adenosine receptors may be useful targets for the treatm

241 n against OIR, effective therapeutic window, adenosine receptor mechanisms, and neuroglial involvemen

242 While previous studies have focused on adenosine-receptor mediated mechanisms for caffeine acti

243 a/HIF-1alpha- and extracellular adenosine/A2 adenosine receptor-mediated immunosuppression protects t

244 cally approved hematopoietic cytokine, in A1 adenosine receptor-mediated induction of sphingosine kin

245 Adenosine receptor-mediated regulation of monocyte/macro

246 ubule IL-11 is a critical intermediary in A1 adenosine receptor-mediated renal protection that warran

247 Adenosine/adenosine receptor-mediated signaling has been implicate

248 TLR-induced production of cytokines through adenosine receptor-mediated signaling.

249 The effects were A1 adenosine receptor-mediated, and the expression of this

250 Levels of CD39, CD73, and adenosine receptor mRNA were differentially modulated by

251 Because stimulation of A2B adenosine receptors on mouse cardiac stem cell antigen (

252 ontribute to disease pathology by activating adenosine receptors on red blood cells.

253 reated with CGS 21680, an agonist of the A2A adenosine receptor or NF449, a P2X1 antagonist.

254 either protect against acute lung injury via adenosine receptors or cause lung injury via adenosine r

255 adenosine receptors or cause lung injury via adenosine receptors or equilibrative nucleoside transpor

256 TP degradation; (2) inhibited P2Y receptors, adenosine receptors, or KATP channels; or (3) inhibited

257 Given the similarity between (adenosine receptors) orthosteric binding sites, obtainin

258 elor and clopidogrel had no direct impact on adenosine receptors (p = not significant).

259 Adenosine receptors participate in many physiological fu

260 ns are complementarily studied as ligands of adenosine receptors, performing radioligand binding assa

261 Because each of these adenosine receptors plays a distinct role throughout the

262 e A(3)AR in HEK293T cells containing a mixed adenosine receptor population.

263 of BRAF and MEK in combination with the A2A adenosine receptor provided significant protection again

264 An increase in adenosine receptor responsiveness to endogenous adenosin

265 Blocking breast cancer cell A3 adenosine receptors resulted in higher extravasation rat

266 Blockade of adenosine receptors selectively increased IPSCs evoked f

267 Transcript levels of renal adenosine receptors showed a selective induction of Ador

268 Adenosine receptor signaling activates cAMP pathway and

269 ptake by inhibition of ENT1/2 would increase adenosine receptor signaling and protect against P. aeru

270 indings suggest that alveolar epithelial A2B adenosine receptor signaling contributes to lung protect

271 ed by enhancing or blocking CD73 activity or adenosine receptor signaling depending on the clinical i

272 otidase-dependent adenosine production or A1-adenosine receptor signaling in the auditory thalamus.

273 along the adenine nucleotide metabolism and adenosine receptor signaling pathways.

274 In this study we showed that adenosine receptor signaling polarizes activated murine

275 protective effect of exogenous cAMP required adenosine receptor signaling.

276 generation of adenosine, but independent of adenosine receptor signaling.

277 To directly deliver an A2B adenosine receptor-specific agonist to alveolar epitheli

278 The response to adenosine receptor stimulation was impaired in eKO mice

279 ation of EF2K occurs in response to A2A-type adenosine receptor stimulation, and that activation of p

280 We show that, after TLR/adenosine receptor stimulation, NR4A2 depletion promotes

281 39) is absolutely conserved across the human adenosine receptor subfamily.

282 Adenosine receptor subtype (A(1), A(2A), A(2B), and A(3)

283 Stimulation of the adenosine receptor subtype A2B increases the gap junctio

284 ed to evaluate the impact of the A2A and A2B adenosine receptor subtype agonist 2-phenylaminoadenosin

285 at the hA(2A)AR, selectivity over all other adenosine receptor subtypes and allowed clear visualizat

286 Expressed adenosine receptor subtypes and connexin (Cx) isoforms w

287 lthough the nature of the immune subsets and adenosine receptor subtypes involved in this process are

288 Several adenosine receptor subtypes on endothelial, epithelial,

289 There are four adenosine receptor subtypes that induce different signal

290 de adenosine (NECA) (10 muM; agonist for all adenosine receptor subtypes) and CGS21680 (10 muM; selec

291 tion, but contrasting signaling profiles, of adenosine receptor subtypes, these compounds might have

292 ation, particularly in the presence of other adenosine receptor subtypes.

293 0.12) and is >650-fold selective over other adenosine receptor subtypes.

294 re of gene-targeted mice for each individual adenosine receptor to liver ischemia and reperfusion rev

295 Molecular dynamics simulations of the A(2A) adenosine receptor totaling 1.4 mus show clear evidence

296 Surface adenosine receptors trigger cyclic AMP (cAMP) formation

297 The A(2A)-adenosine receptor undergoes restricted collision coupli

298 ently inhibited by activation of presynaptic adenosine receptors, whereas IPSCs evoked from RMTg were

299 P formation and hypertrophy by activating A1 adenosine receptors while delivering an antifibrotic sig

300 These effects were mimicked by antagonism of adenosine receptors with 8-(p-sulfophenyl) theophylline.